EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC 4.0

A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection

Carmelo Scarpignato iD, Colin W Howden iD, Eckhard Leifke, Darcy J Mulford, Gezim Lahu, Axel Facius, Richard Hunt iD

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17510 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2023. Written by Carmelo Scarpignato and 6 co-authors. Institution: Department of Health Sciences, United Campus of Malta, Msida, Malta. Major MEDLINE topics: Helicobacter Infections, Helicobacter pylori, Peptic Ulcer, Esophagitis. Cited 18 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Treatment of acid‐related disorders relies on gastric acid suppression. The percentage of time intragastric pH is >4 (pH >4 holding time ratio [HTR]) is important for healing erosive oesophagitis; and the pH >6 HTR is critical for eradication of Helicobacter pylori infection, as bacterial replication is active and antibiotic effectiveness is optimised. Vonoprazan, a potassium‐competitive acid blocker approved in the USA and other countries, suppresses gastric acid secretion in a predictable, rapid and consistent manner, extended over prolonged periods.

Aim

To explore the relationship between vonoprazan exposure and pH HTR through a pharmacokinetic/pharmacodynamic (PK/PD) model.

Methods

We pooled data from Phase 1 studies with intragastric pH measurements. Pharmacokinetic profiles were predicted for study participants using an existing population pharmacokinetic model. Pharmacokinetic and pharmacodynamic data were merged, and three direct‐link PK/PD models were derived and used to simulate pH HTRs with between‐participant variability for pH >4, >5 and >6, for vonoprazan doses of 20 mg once and twice daily.

Results

We used data from five Phase 1 studies to derive the PK/PD model. These included 245 participants (95.1% male, 50.6% Japanese and 49.4% non‐Asian). Pre‐dose, the mean pH >4 HTR was 6.4%, pH >5 3.2% and pH >6 1.2%. After 7 days of dosing, simulations predicted pH >4 HTRs of 89.7% and 98.1%, and pH >6 HTRs of 53.1% and 75.3%, for vonoprazan 20 mg once and twice daily, respectively.

Conclusions

Vonoprazan 20 mg once‐ and twice‐daily dosing demonstrated high, dose‐dependent, 24‐hour intragastric acid control in this PK/PD model, supporting clinical efficacy data in patients with acid‐related disorders.

Subjects

MeSH terms (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriPeptic UlcerEsophagitisHumansMaleFemaleProton Pump InhibitorsPyrrolesSulfonamides

Substances

Proton Pump InhibitorsPyrroles1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamides

Authors and institutions

  • Department of Health Sciences, United Campus of Malta, Msida, Malta.
  • University of Tennessee College of Medicine, Memphis, Tennessee, USA.
  • Phathom Pharmaceuticals, Research and Development, Buffalo Grove, Illinois, USA.
  • thinkQ2 AG, Oberneuhofstrasse 5, Baar, Switzerland.
  • Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
  • Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

ORCID profiles: Carmelo Scarpignato, Colin W Howden, Richard Hunt

Cite

APA

Scarpignato, C., Howden, C. W., Leifke, E., Mulford, D. J., Lahu, G., Facius, A., & Hunt, R. (2023). A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17510

Vancouver

Scarpignato C, Howden CW, Leifke E, Mulford DJ, Lahu G, Facius A, et al. A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17510

BibTeX
@article{Scarpignato2023,
  author = {Scarpignato, Carmelo and Howden, Colin W and Leifke, Eckhard and Mulford, Darcy J and Lahu, Gezim and Facius, Axel and Hunt, Richard},
  title = {A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17510}
}
Start for free →